DOCSLIB.ORG

Tricyclic Thrombin Receptor Antagonists Trizyklische Thrombin Rezeptor Antagonisten Antagonistes Tricycliques Du Recepteur De Thrombine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tricyclic Thrombin Receptor Antagonists Trizyklische Thrombin Rezeptor Antagonisten Antagonistes Tricycliques Du Recepteur De Thrombine (19) TZZ_Z__T (11) EP 1 495 018 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 405/06 (2006.01) A61K 31/44 (2006.01) 14.11.2007 Bulletin 2007/46 A61P 7/02 (2006.01) A61P 9/00 (2006.01) A61P 9/04 (2006.01) A61P 9/06 (2006.01) (2006.01) (2006.01) (21) Application number: 03718393.6 A61P 9/10 A61P 9/12 A61P 35/00 (2006.01) A61P 43/00 (2006.01) (22) Date of filing: 14.04.2003 (86) International application number: PCT/US2003/011510 (87) International publication number: WO 2003/089428 (30.10.2003 Gazette 2003/44) (54) TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS TRIZYKLISCHE THROMBIN REZEPTOR ANTAGONISTEN ANTAGONISTES TRICYCLIQUES DU RECEPTEUR DE THROMBINE (84) Designated Contracting States: • XIA, Yan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Edison, NJ 08820 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • VELTRI, Enrico, P. Designated Extension States: Princeton, NJ 08540 (US) AL LT LV MK • CHELLIAH, Mariappan Edison, NJ 08817 (US) (30) Priority: 16.04.2002 US 373072 P • WU, Wenxue Princeton Junction, (43) Date of publication of application: NJ 08550 (US) 12.01.2005 Bulletin 2005/02 (74) Representative: Siegert, Georg (60) Divisional application: Hoffmann - Eitle 07016461.1 Patent- und Rechtsanwälte Arabellastrasse 4 (73) Proprietor: Schering Corporation 81925 München (DE) Kenilworth, New Jersey 07033-0530 (US) (56) References cited: (72) Inventors: WO-A-01/96330 WO-A-99/26943 • CHACKALAMANNIL, Samuel US-A- 6 063 847 Califon, NJ 07830 (US) • CLASBY, Martin, C. Remarks: Plainsboro, NJ 08536 (US) Thefilecontainstechnicalinformationsubmittedafter • GREENLEE, William, J. the application was filed and not included in this Teaneck, NJ 07666 (US) specification • WANG, Yuguang North Brunswick, NJ 08902 (US) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 495 018 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 495 018 B1 Description BACKGROUND OF THE INVENTION 5 [0001] The present invention relates to substituted tricyclic thrombin receptor antagonists, pharmaceutical composi- tions containing them and their use in the treatment of diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, cerebral ischemia, stroke, inflammatory disorders, neurodegen- erative diseases and cancer. The invention also relates to the combination of novel compounds of the invention and other cardiovascular agents. 10 [0002] Thrombin is known to have a variety of activities in different cell types and thrombin receptors are known to be present in such cell types as human platelets, vascular smooth muscle cells, endothelial cells and fibroblasts. It is therefore possible that thrombin receptor antagonists, also known as protease activated receptor (PAR) antagonists will be useful in the treatment of thrombotic, inflammatory, atherosclerotic and fibroproliferative disorders, as well as other disorders in which thrombin and its receptor play a pathological role. 15 [0003] Thrombin receptor antagonists peptides have been identified based on structure-activity studies involving substitutions of amino acids on thrombin receptors. In Bematowicz et al, J. Med. Chem., vol. 39, pp. 4879-4887 (1996) , tetra- and pentapeptides are disclosed as being potent thrombin receptor antagonists, for example N-trans-cinnamoyl- p-fluoroPhe-p-guanidinoPhe-Leu-Arg-NH2 and N-trans-cinnamoyl-p-fluoroPhe-p-guanidinoPhe-Leu-Arg-Arg-NH2. Peptide thrombin receptor antagonists are also disclosed in WO 94/03479, published February 17, 1994. 20 [0004] Substituted tricyclic thrombin receptor antagonists are disclosed in US 6,063,847, US 6,326,380 and U.S. Serial Nos. 09/880222 (WO 01/96330) and 10/271715. SUMMARY OF THE INVENTION 25 [0005] The present invention relates to thrombin receptor antagonists represented by the Formula I: 30 35 40 or a pharmaceutically acceptable salt or solvate thereof, wherein: 45 ----- represents an optional double bond; n is 0-2; Q is 50 55 2 EP 1 495 018 B1 5 10 15 1 R is independently selected from the group consisting of H and (C1-C6)alkyl; R2 is independently selected from the group consisting of H and (C1-C6)alkyl; 17 22 23 R3 is H, hydroxy, (C1-C6)alkoxy, -C(O)OR , (C1-C6)alkyl, halogen, (C3-C6)cycloalkyl or -NR R ; Het is pyridyl, wherein a ring nitrogen can form an N-oxide or a quaternary group with a (C1-C4)alkyl group, wherein Het is attached to B by a carbon atom ring member, and wherein the Het group is substituted by W; 20 W is 1 to 4 substituents independently selected from the group consisting of R21-aryl and R21-heretoaryl; 4 5 R and R are independently selected from the group consisting of H, (C1-C6)alkyl, phenyl, benzyl and (C3-C6) 4 5 7 cycloalkyl, or R and R taken together are -(CH2)4-, -(CH2)5- or -(CH2)2NR -(CH2)2- and form a ring with the nitrogen to which they are attached; R8,R10 and R11 are independently selected from the group consisting of R1 and -OR1, provided that when the 25 optional double bond is present, R10 is absent; 9 - R is H, OH or (C1-C6)alkoxy; B is -CH=CH-; 13 16b each R is independently selected from H, (C1-C6)alkyl (C3-C8)cycloalkyl, -(CH2)n6NHC(O)OR , -(CH2)n6NHC 16b 4 5 16 4 5 28 29 (O)R , -(CH2)n6NHC(O)NR R , -(CH2)n6NHSO2R , -(CH2)n6NHSO2NR R , and -(CH2)n6C(O)NR R where 30 n6 is 0-4, haloalkyl, and halogen; 14 27 each R is independently selected from H, (C1-C6)alkyl, -OH, (C1-C6)alkoxy, R -aryl(C1-C6)alkyl, heteroaryl, het- 16b 16b 4 5 eroarylalkyl, heterocyclyl, heterocyclylalkyl, -(CH2)n6NHC(O)OR , -(CH2)n6NHC(O)R , -(CH2)n6NHC(O)NR R , 16 4 5 28 29 -(CH2)n6NHSO2R , -(CH2)n6NHSO2NR R , and -(CH2)n6C(O)N R where n6 is 0-4, halogen and haloalkyl; or R13 and R14 taken together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms; 35 13 14 16b wherein at least one of R or R is selected from the group consisting of -(CH2)n6NHC(O)OR , -(CH2)n6NHC 16b 4 5 16 4 5 (O)R , -(CH2)n6NHC(O)NR R , -(CH2)n6NHSO2R , -(CH2)n6NHSO2NR R ; n6 is 0-4; 16 R is independently selected from the group consisting of (C1-C6)alkyl, phenyl and benzyl; 16b 22 21 R is H, alkoxy, (C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl-, R -O-C(O)-(C1-C6)alkyl-, (C3-C6)cycloalkyl, R -aryl, 40 21 21 R -aryl(C1-C6)alkyl, haloalkyl, alkenyl, halosubstituted alkenyl, alkynyl, halosubstituted alkynyl, R -heteroaryl, 21 21 28 29 28 29 R -(C1-C6)alkyl heteroaryl, R -(C1-C6)alkyl heterocycloalkyl, R R N-(C1-C6)alkyl, R R N-(CO)-(C1-C6)alkyl, 28 29 28 29 28 29 28 29 R R N-(CO)O-(C1-C6)alkyl, R O(CO)N(R )-(C1-C6)alkyl, R S(O)2N(R )-(C1-C6)alkyl, R R N-(CO)-N 29 28 29 29 28 29 20 29N (R )- (C1-C6)alkyl, R R N-S(O)2N(R )-(C1-C6)alkyl, R -(CO)N(R )-(C1-C6)alkyl. R R -S(O)2-(C1-C6) 28 28 alkyl, HOS(O)2-(C1-C6)alkyl, (OH)2P(O)2-(C1-C6)alkyl, R -S-(C1-C6)alkyl, R -S(O)2-(C1-C6)alkyl or hydroxy 45 (C1-C6)alkyl); 17 R is independently selected from the group consisting of H, (C1-C6)alkyl, phenyl, and benzyl; 21 R is 1 to 3 substituents independently selected from the group consisting of H, -CN, -CF3, -OCF3, halogen, -NO2, 25 26 (C1-C6)alkyl, -OH, (C1-C6)alkoxy, (C1-C6)-alkylamino-, di-((C1-C6)alkyl)amino-, NR R -(C1-C6)alkyl-, hy- 17 17 16 16 25 26 25 droxy-(C1-C6)alkyl-,-C(O)OR , -C(O)R , -NHCOR , -NHSO2R , -NHSO2CH2CF3, -C(O)NR R ,-NR -C 50 25 26 13 13 13 (O)-NR R , -S(O)R , -S(O)2R and -SR ; 22 R is H or (C1-C6)alkyl; 23 24 24 24 24 R is H, (C1-C6)alkyl, -C(O)R , -SO2R , -C(O)NHR or -SO2NHR ; 24 25 26 R is (C1-C6)alkyl, hydroxy (C1-C6)alkyl or NR R -((C1-C6)alkyl)-; 25 26 R and R are independently selected from the group consisting of H and (C1-C6)alkyl; 55 27 R is 1, 2 or 3 substituents selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, halogen and -OH; and 28 29 27 R and R are independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)alkoxy, R -aryl(C1-C6) alkyl, heteroaryl, heteroarylalkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, heterocyclyl, heterocyclylalkyl, 3 EP 1 495 018 B1 and haloalkyl; or R28 and R29 taken together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms. [0006] Thrombin receptor antagonist compounds of the present invention can have anti-thrombotic, anti-platelet ag- 5 gregation, antiatherosclerotic, antirestenotic and/or anti-coagulant activity. Thrombosis-related diseases treated by the compounds of this invention include thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic and thromboembolytic stroke, peripheral vascular diseases, other cardiovascular diseases, cerebral ischemia, inflammatory disorders and cancer, as well as other disorders in which thrombin and its receptor play a pathological role.
Load more

Recommended publications
  • Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor
    Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor Raja Chakraborty1,3, Rajinder P. Bhullar1, Shyamala Dakshinamurti2,3, John Hwa4, Prashen Chelikani1,2,3* 1 Department of Oral Biology, University of Manitoba, Winnipeg, Manitoba, Canada, 2 Departments of Pediatrics, Physiology, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Biology of Breathing Group- Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada, 4 Department of Internal Medicine (Cardiology), Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, United States of America Abstract G protein-coupled receptors (GPCRs) show some level of basal activity even in the absence of an agonist, a phenomenon referred to as constitutive activity. Such constitutive activity in GPCRs is known to have important pathophysiological roles in human disease. The thromboxane A2 receptor (TP) is a GPCR that promotes thrombosis in response to binding of the prostanoid, thromboxane A2. TP dysfunction is widely implicated in pathophysiological conditions such as bleeding disorders, hypertension and cardiovascular disease. Recently, we reported the characterization of a few constitutively active mutants (CAMs) in TP, including a genetic variant A160T. Using these CAMs as reporters, we now test the inverse agonist properties of known antagonists of TP, SQ 29,548, Ramatroban, L-670596 and Diclofenac, in HEK293T cells. Interestingly, SQ 29,548 reduced the basal activity of both, WT-TP and the CAMs while Ramatroban was able to reduce the basal activity of only the CAMs. Diclofenac and L-670596 showed no statistically significant reduction in basal activity of WT-TP or CAMs. To investigate the role of these compounds on human platelet function, we tested their effects on human megakaryocyte based system for platelet activation.
    [Show full text]
  • Increased Serum Thromboxane A2 and Prostacyclin but Lower Complement C3 and C4
    medRxiv preprint doi: https://doi.org/10.1101/2021.04.10.21255240; this version posted April 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 Increased serum thromboxane A2 and prostacyclin but lower complement C3 and C4 levels in COVID-19: associations with chest CT-scan anomalies and lowered peripheral oxygen saturation. Hussein Kadhem Al-Hakeim a, Shaymaa Ali Al-Hamami, b, Michael Maes c, d, e. a Department of Chemistry, College of Science, University of Kufa, Iraq. E-mail: [email protected] b Department of Medical Laboratory Techniques, Altoosi University College, Najaf, Iraq. E-mail: [email protected] c Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria. d Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. e School of Medicine, IMPACT Strategic Research Centre, Deakin University, PO Box 281, Geelong, VIC, 3220, Australia. Corresponding author: Prof. Dr. Michael Maes, M.D., Ph.D., IMPACT Strategic Research Center, Barwon Health, Deakin University, Geelong, Vic, Australia. E-mail: [email protected]. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.04.10.21255240; this version posted April 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Nippon Shinyaku (4516)
    01 September 2016 Asia Pacific/Japan Equity Research Specialty Pharmaceuticals (Pharmaceuticals (Japan)) / MARKET WEIGHT Nippon Shinyaku (4516 / 4516 JP) Rating OUTPERFORM* Price (31 Aug 16, ¥) 4,795 INITIATION Target price (¥) 6,300¹ Chg to TP (%) 31.4 Early entry into niche indications paying off Market cap. (¥ bn) 323.65 (US$ 3.13) Enterprise value (¥ bn) 302.35 ■ Initiating coverage at OUTPERFORM with target price of ¥6,300 Number of shares (mn) 67.50 Free float (%) 55.0 (potential return 31%): We expect Nippon Shinyaku to be the next 52-week price range 5,960 - 3,760 Japanese pharmaceutical company to benefit from the global launch of *Stock ratings are relative to the coverage universe in each Uptravi (selexipag), an internally-discovered drug of blockbuster calibre; and analyst's or each team's respective sector. a strong partnership. The company shifted focus to niche indications almost ¹Target price is for 12 months. a decade ago, and this strategy is on its way to paying off, in our view. Research Analysts ■ Uptravi (selexipag) the biggest driver: Selexipag was originally Yen Ting Chen, PhD 81 3 4550 9936 discovered by Nippon Shinyaku and ex-Japan rights licensed to Actelion. In [email protected] January 2016, selexipag was launched in the US market for pulmonary Fumiyoshi Sakai arterial hypertension (PAH) followed by Germany in June. We forecast peak 81 3 4550 9737 sales of $1.65bn globally, with ¥17.5bn in Japan for the PAH market. With [email protected] additional revenue from royalties and manufacturing, we expect total revenue from selexipag to reach ¥39bn for Nippon Shinyaku in FY3/21.
    [Show full text]
  • Prostaglandin E2–Prostoglandin E Receptor Subtype 4 (EP4) Signaling Mediates UV Irradiation-Induced Systemic Immunosuppression
    Prostaglandin E2–prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression Kitipong Soontrapaa,b, Tetsuya Hondaa,c, Daiji Sakataa, Chengcan Yaoa, Takako Hirataa, Shohei Horid, Toshiyuki Matsuokaa, Yoshihiro Kitae, Takao Shimizue, Kenji Kabashimac, and Shuh Narumiyaa,f,1 aDepartment of Pharmacology, cDepartment of Dermatology, and fJapan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), Kyoto University Faculty of Medicine, Kyoto 606-8501, Japan; bDepartment of Pharmacology, Mahidol University Faculty of Medicine, Siriraj Hospital, Bangkok 10700, Thailand; dResearch Unit for Immune Homeostasis, RIKEN Research Center for Allergy and Immunology, Yokohama 230-0045, Japan; and eDepartment of Biochemistry and Molecular Biology, University of Tokyo Faculty of Medicine, Tokyo 113-0033, Japan Edited* by Salvador Moncada, University College of London, London, United Kingdom, and approved March 2, 2011 (received for review December 11, 2010) UV radiation induces systemic immunosuppression. Because non- induction of Treg cells through activating epidermal dendritic steroidal anti-inflammatory drugs suppress UV-induced immuno- cells (DCs) expressing DEC205, which recently were confirmed + suppression, prostanoids have been suspected as a crucial mediator to be specialized to induce forkhead box P3-positive (Foxp3 ) of this UV effect. However, the identity of the prostanoid involved Treg cells (15). However, definite proof of the involvement of and its mechanism of action remain unclear. Here, we addressed this RANKL and Treg cells in UV-induced systemic immunosup- issue by subjecting mice deficient in each prostanoid receptor pression has yet to be obtained. individually or mice treated with a subtype-specific antagonist to Among the factors involved in UV-induced immunosuppres- UV irradiation.
    [Show full text]
  • 10006735.Pdf
    PRODUCT INFORMATION CAY10471 Item No. 10006735 CAS Registry No.: 627865-18-3 HOOC Formal Name: (+)-3-[[(4-fluorophenyl)sulfonyl] methylamino]-1,2,3,4-tetrahydro- 9H-carbazole-9-acetic acid N Synonym: TM30089 O MF: C21H21FN2O4S O FW: 416.5 S Purity: ≥95% N Supplied as: A crystalline solid Storage: -20°C F Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures CAY10471 is supplied as a crystalline solid. CAY10471 is supplied as a crystalline solid. A stock solution may be made by dissolving the CAY10471 in an organic solvent purged with an inert gas. CAY10471 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CAY10471 in these solvents is approximately 15 mg/ml in ethanol and approximately 30 mg/ml in DMSO and DMF. CAY10471 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CAY10471 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CAY10471 has a solubility of approximately 0.5 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description The biological effects of PGD2 are transduced by at least two 7-transmembrane G-protein coupled receptors, designated DP1 and CRTH2/DP2. BAY-u3405 (Ramatroban) is an approved human medication for the treatment of allergic rhinitis that has documented activity as an antagonist of 1,2 both the TP and CRTH2/DP2 receptors.
    [Show full text]
  • Prostanoid Receptors (Version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F58/2019.5 Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database Richard M. Breyer1, Lucie Clapp2, Robert A. Coleman3, Mark Giembycz4, Akos Heinemann5, Rebecca Hills6, Robert L. Jones7, Shuh Narumiya8, Xavier Norel9, Roy Pettipher10, Yukihiko Sugimoto11, Mohib Uddin12, David F. Woodward13 and Chengcan Yao6 1. Vanderbilt University, USA 2. University College London, UK 3. Pharmagene Laboratories, UK 4. University of Calgary, Canada 5. Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Austria 6. University of Edinburgh, UK 7. University of Strathclyde, UK 8. Kyoto University Faculty of Medicine, Japan 9. Laboratory for Vascular Translational Science, France 10. Atopix Therapeutics Ltd, UK 11. Kumamoto University, Japan 12. AstraZeneca, Sweden 13. Allergan plc, USA Abstract Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [659]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies. Contents This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them.
    [Show full text]
  • Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current
    Bench to Clinic Symposia EDITORIAL REVIEW Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions DOMINICK J. ANGIOLILLO, MD, PHD of low-dose aspirin (75–162 mg/day) as a primary prevention strategy in patients with type 1 or type 2 diabetes at increased Ͼ ardiovascular disease is the leading patients undergoing percutaneous coro- cardiovascular risk, including those 40 cause of morbidity and mortality in nary interventions (PCI) (4). However, years of age or who have additional risk C patients with diabetes (1). The con- these agents are available only for paren- factors (family history of cardiovascular comitant presence of multiple classical teral use and have a short duration of ac- disease, hypertension, smoking, dyslipi- cardiovascular risk factors in diabetic tion, which impedes their use for long- demia, or albuminuria) (8). However, subjects contributes to enhanced athero- term protection. The need for alternative aspirin therapy should not be recom- thrombotic risk (2). However, other risk antiplatelet treatment strategies led to the mended for patients aged Ͻ21 years be- factors may be important such as abnor- evaluation of effects obtained from a com- cause this may increase the risk of Reye’s mal platelet function (3). Platelets, in fact, bination of oral antiplatelet agents inhib- syndrome. The role of aspirin in diabetic play a key role in atherogenesis, and its iting other platelet-activating pathways. patients aged Ͻ30 years remains unclear thrombotic complications and measures, Ticlopidine is a first-generation thienopy- because it has not been investigated. which lead to blockade of one or multiple ridine, which irreversibly blocks the Several clinical trials have evaluated the efficacy of aspirin in diabetic patients pathways modulating platelet activation platelet ADP P2Y12 receptor (6).
    [Show full text]
  • 2621.Full.Pdf
    Prostaglandin D2 Plays an Essential Role in Chronic Allergic Inflammation of the Skin via CRTH2 Receptor This information is current as Takahiro Satoh, Rie Moroi, Kosuke Aritake, Yoshihiro of September 29, 2021. Urade, Yasumasa Kanai, Koji Sumi, Hiroo Yokozeki, Hiroyuki Hirai, Kinya Nagata, Toshifumi Hara, Masanori Utsuyama, Katsuiku Hirokawa, Kazuo Sugamura, Kiyoshi Nishioka and Masataka Nakamura J Immunol 2006; 177:2621-2629; ; Downloaded from doi: 10.4049/jimmunol.177.4.2621 http://www.jimmunol.org/content/177/4/2621 References This article cites 36 articles, 13 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/177/4/2621.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online
    [Show full text]
  • Harnessing DNA-Encoded Libraries to Discover Bioactive Small Molecules
    Harnessing DNA-Encoded Libraries to Discover Bioactive Small Molecules The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Chan, Alix I. 2018. Harnessing DNA-Encoded Libraries to Discover Bioactive Small Molecules. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41128464 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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
    [Show full text]
  • Antagonism of the Prostaglandin D Receptors DP and CRTH2 As An
    REVIEWS Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases Roy Pettipher*, Trevor T. Hansel‡ and Richard Armer* Abstract | Immunological activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases. Pharmacological studies using the recently discovered DP1 and CRTH2 antagonists combined with genetic analysis support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy. This Review focuses on the emerging roles that DP1 and CRTH2 (also known as DP2) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state. We also discuss recent progress in the discovery and development of selective antagonists of these receptors. Prostaglandin Prostaglandins D2 (PGD2) is an acidic lipid mediator that leads to the rapid production of PGD2, which can be Acidic lipids derived from the is derived from arachidonic acid by the sequential action detected in the bronchoalveolar lavage fluid within metabolism of arachidonic acid of cyclooxygenase(s) (COX) and PGD2 synthase(s). The minutes, reaching biologically active levels at least by the action of cyclo- COX(s) convert arachidonic acid in a two-step process 150-fold higher than pre-allergen levels10. Local anti- oxygenase enzymes and to first PGG and then PGH . These unstable endoper- gen challenge also stimulates PGD production in the downstream synthase 2 2 2 11 enzymes. Prostaglandins have oxide intermediates are converted to PGD2 by either the nasal mucosa of patients with allergic rhinitis and in (FIG.
    [Show full text]
  • Head Injury Partial Update
    Head Injury partial update Literature search strategies Appendix A: Literature search strategies Contents Introduction Search methodology Section A.1 Population search strategies A.1.1 Head injury A.1.2 General trauma A.1.3 Spinal injury Section A.2 Study filter terms A.2.1 Excluded studies designs and publication types A.2.2 Observational studies A.2.3 Patient views A.2.4 Qualitative studies A.2.5 Predictive rules A.2.6 Triage A.2.7 Economic studies A.2.8 Quality of life Section A.3 Searches for specific questions with intervention A.3.1 Direct transport to hospital A.3.2 Imaging A.3.3 Anticoagulants A.3.4 Biomarkers A.3.5 Cervical spine A.3.6 Patient information Section A.4 Economic searches A.4.1 Economic reviews A.4.2 Quality of Life in anticoagulation patients and cervical spine patients Section A.5 References Search strategies used for the Head Injury guideline are outlined below and were run in accordance with the methodology in the NICE Guidelines Manual 2009.{National Institute for Health and Clinical Excellence, 2009 NICE2009 /id} All searches were run up to 31 May 2013 unless otherwise stated. Any studies added to the databases after this date were not included unless specifically stated in the text. Where possible searches were limited to retrieve material published in English. Searches to update questions covered in the previous NICE guidance on Head injury (reference) were limited to retrieve material published since the date of the original searches for that guideline. The date limitations for each search are indicated with the searches below.
    [Show full text]
  • Inflammation/Immunology
    Inflammation/Immunology The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. www.MedChemExpress.com 1 Inflammation/Immunology Inhibitors & Modulators (+)-Borneol (+)-DHMEQ ((1R,2R,6R)-Dehydroxymethylepoxyquinomicin; (d-Borneol) Cat. No.: HY-N1368A (1R,2R,6R)-DHMEQ) Cat. No.: HY-14645A Bioactivity: (+)-Borneol (d-Borneol) is a natural bicyclic monoterpene used Bioactivity: (+)-DHMEQ is an activator of antioxidant transcription factor for analgesia and anesthesia in traditional Chinese medicine; Nrf2. (+)-DHMEQ is the enantiomer of (-)-DHMEQ. (-)-DHMEQ enhances GABA receptor activity with an EC50 of 248 μM. inhibits NF-kB than its enantiomer (+)-DHMEQ. Purity: 98.0% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 2 mg, 5 mg, 10 mg, 25 mg (-)-Epicatechin (-)-Ketoconazole ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 Cat. No.: HY-B0105B Bioactivity: (-)-Epicatechin inhibits cyclooxygenase-1 ( COX-1) with an Bioactivity: (-)-Ketoconazole is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the levoketoconazole ((2S,4R)-(−)-ketoconazole) and p65 subunit of NF-κB.
    [Show full text]